Becton Dickinson and Co (BDX) Statistics

Becton Dickinson and Co (BDX) is a leading medical technology company that specializes in the development, manufacture, and sale of innovative healthcare products. As of the latest valuation metrics, BDX has a market capitalization of $70.5 billion. The stock is evaluated based on various key financial indicators to assess its overall value. BDX has a forward price-to-earnings ratio of 19.8, indicating reasonable valuation. The price-to-sales ratio stands at 2.9, suggesting that the stock is trading at a moderate multiple of its revenue. BDX also has a price-to-book value ratio of 3.4, indicating that the stock is trading at a slight premium to its book value.

When it comes to fundamentals, BDX has a solid track record. The company has consistently delivered revenue growth, with a revenue per share of $37.2. This demonstrates its ability to generate substantial sales per outstanding share. BDX also boasts a healthy profit margin of 12.6%, indicating its efficiency in translating revenue into profit. Furthermore, the company has managed its debt levels prudently, with a total debt of $18.2 billion. This suggests that BDX has a manageable level of debt relative to its overall financial position. Additionally, BDX has a strong gross profit of $8.9 billion, highlighting its ability to generate profits after accounting for the cost of goods sold.